Cellceutix Hits Major Milestone in Company History; Dosing Underway for New Cancer Drug at Leading Hospitals

Kevetrin is First-in-Class of Novel Chemistry to Reach Clinical Stage

Cellceutix Corporation (OTCBB: CTIX) (the “Company”), a clinical stage biopharmaceutical company focused on discovering small molecule drugs to treat unmet medical conditions, including drug-resistant cancers and autoimmune diseases, is pleased to report that dosing of patients is now being conducted in clinical trials with Kevetrin(TM), the Company’s novel anti-cancer drug candidate, at Harvard University’s Dana Farber Cancer Center and Beth Israel Deaconess Medical Center. Read More

The countdown has begun for Cellceutix to begin testing their lead compound, anti-cancer drug Kevetrin, at Dana-Farber and Beth Israel Deaconess.  After a mild setback with Formatech going bankrupt, the company has completed the necessary changes to the Investigational New Drug application related to Quality Control testing and stability studies through a new supplier and added the data to the IND.  This is great news for biotech traders and Cellceutix faithful as investors are eager to see the new drug in humans because Read More

Mass High Tech ran the story last Thursday after Cellceutix Corporation (OTCBB: CTIX) submitted a regulatory filing with the Security and Exchange Commission related to securing the funds, but this morning the company released press discussing their securing of $1 million in financing for their planned clinical trials on Kevetrin™, their flagship anti-cancer drug.  The trials are slated to be held at Harvard’s Dana-Farber Cancer Institute. Read More

The latest edition of TheStreetBeat.com’s CEO Interview series features Cellceutix Chief Executive Officer Leo Ehrlich. The interview is being released in two parts, with Part One of the interview released this afternoon and Part Two slated Read More

This one day might be the story called “The Little Biotech That Could”.  Cellceutix Corp. (OTCBB: CTIX) has a pipeline of eight drugs with three that have already begun clinical trials (one for cancer, one for psoriasis and one for autism).   The flagship drug, Kevetrin™ is being developed as an anti-cancer drug with clinical trials slated to be hosted at the vaunted Dana-Farber Cancer Center. Read More

Cellceutix Corporation (OTCQB: CTIX) is pleased to report that it has submitted for review the “Investigator’s Brochure and Clinical Protocol” sections of its Investigational New Drug (IND) application for Kevetrin™, Cellceutix’s drug in development as a treatment for cancers, to the world-renowned hospital in which it expects to host its Phase I clinical trials. Upon review by the cancer center, Cellceutix will add the documents to the IND for submission to the FDA.

Leo Ehrlich, CEO of Cellceutix, stated,

“I would like to congratulate the Cellceutix team including our many consultants, shareholders, and vendors on this important event. Yes, many thought it was impossible to accomplish what we have achieved. Not only have we have created a new chemical class and breakthrough in medicine; we completed this at amazing speed, about three years, and expect shortly to file our IND. We are working diligently to see Cellceutix flourish and believe the best is yet to come.”

Cellceutix Corporation (CTIX) Stock Quote and News:

Cellceutix Cancer Drug, Kevetrin™, Shows Increased Levels of p21; Biomarker for Cancer Trials

Cellceutix Corporation (OTCQB:CTIX), a biopharmaceutical company focused on discovering and developing small molecule drugs to treat severe medical conditions including drug-resistant cancers,  is pleased to announce that additional research has been concluded on Kevetrin™, the Company’s flagship cancer compound.  Kevetrin was shown to increase levels of p21, a key protein responsible for cell cycle arrest, in the lymphocytes of mice.  Cellceutix will be incorporating the p21 assay into its Investigational New Drug application scheduled to be filed with the Food and Drug Administration in approximately six weeks.  If the data are duplicated in human studies, p21 as a biomarker will be another major step forward in cancer research for Kevetrin™, which has already been shown to be a non-genotoxic drug that reactivates p53; a major development of its own.

Dr. Krishna Menon, Chief Scientific Officer for Cellceutix, commented, “There has been a big movement in the oncology industry to establish new biomarkers as they are an earlier measure of activity in the body’s cells.  p21 has been proven to play a critical role in cell cycle arrest leading to cell death.  No one has been able to validate it as a biomarker, to the best of our knowledge, so this will be a major event not only for Cellceutix, but for the cancer clinical trials.”  Dr. Menon continued, “Increased levels of p21 are not only a predictor of cell death, but a benchmark in judging effectiveness of Kevetrin™.  Our pre-clinical research on p21 has met its endpoints and we are optimistic that the upcoming human trials will yield similar results.”

Cellceutix Corporation (CTIX) Stock Quote and News: